Jasper Therapeutics Inc

NASDAQ:JSPRUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Nov 9, 2023

Show headlines and story abstract

• Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update, from 8:00AM ET on Thursday Nov 09, 2023 by Dow Jones

  8:00AM ET on Thursday Nov 09, 2023 by Dow Jones
  Companies Mentioned: JSPR
  
  --- tables to follow---
  JASPER THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) (unaudited) Three Months Ended Nine Months Ended September September 30, 30, --------------------------- ----------------------------- 2023 2022 2023 2022 Operating expenses Research and development(1) $ 14,848 $ 9,022 $ 37,950 $ 25,345 General and administrative(1) 4,514 3,686 13,186 12,104 Total operating expenses 19,362 12,708 51,136 37,449 ----------- ---------- ----------- ---------- Loss from operations (19,362) (12,708) (51,136) (37,449) Interest income 1,433 259 3,965 353 Change in fair value of earnout liability 334 422 (10) 5,640 Change in fair value of common stock warrant liability -- 155 (575) 7,050 Other income (expense), net 51 9 (128) (68) ----------- ---------- ----------- ---------- Total other income, net 1,818 845 3,252 12,975 ----------- ---------- ----------- ---------- Net loss and comprehensive loss $ (17,544) $ (11,863) $ (47,884) $ (24,474) =========== ========== =========== ========== Net loss per share attributable to common stockholders, basic and diluted $ (0.16) $ (0.32) $ (0.47) $ (0.67) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 109,720,741 36,565,650 102,351,140 36,425,000 =========== ========== =========== ========== (1) Amounts include non-cash stock based compensation expense as follows (in thousands): Three Months Ended Nine Months Ended September September 30, 30, --------------------------- ----------------------------- 2023 2022 2023 2022 ----------- ---------- ----------- ---------- Research and development $ 381 $ 169 $ 1,340 $ 976 General and administrative 1,014 475 2,713 1,511 Total $ 1,395 $ 644 $ 4,053 $ 2,487 =========== ========== =========== ========== JASPER THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) September 30, December 31, Assets 2023 2022 Current assets: Cash and cash equivalents $ 103,867 $ 38,250 Other receivables - 663 Prepaid expenses and other current assets 1,351 2,818 ---------- --------- Total current assets 105,218 41,731 Property and equipment, net 2,780 3,568 Operating lease right-of-use assets 1,579 1,886 Restricted cash 417 417 Other non-current assets 411 759 Total assets $ 110,405 $ 48,361 ========== ========= Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 3,256 $ 1,768 Current portion of operating lease liabilities 945 865 Current portion of earnout liability 28 -- Accrued expenses and other current liabilities 7,677 4,432 ---------- --------- Total current liabilities 11,906 7,065 Non-current portion of operating lease liabilities 2,069 2,786 Common stock warrant liability -- 150 Non-current portion of earnout liability -- 18 Other non-current liabilities 2,297 2,353 Total liabilities 16,272 12,372 ---------- --------- Commitments and contingencies Stockholders' equity: Preferred stock -- -- Common stock 11 4 Additional paid-in capital 247,141 141,120 Accumulated deficit (153,019) (105,135) ---------- --------- Total stockholders' equity 94,133 35,989 ---------- --------- Total liabilities and stockholders' equity $ 110,405 $ 48,361 ========== =========
  

• Press Release: Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update, from 8:00AM ET on Thursday Nov 09, 2023 by Dow Jones

  8:00AM ET on Thursday Nov 09, 2023 by Dow Jones
  Companies Mentioned: JSPR